Logo
x

Search

Subscribe Now

Biosimilar

Xbrane Resubmit the BLA for Ranibizumab Biosimilar to Treat Serious Eye Disease

Xbrane Resubmit the BLA for Ranibizumab Biosimilar to Treat Serious Eye Disease

  • July 4, 2022
Samsung Bioepis & Celltrion Report Results of CT-P13 and SB2 (biosimilar, infliximab) in Prospective Study for the Treatment of Inflammatory Bowel Disease

Samsung Bioepis & Celltrion Report Results of CT-P13 and SB2 (biosimilar, infliximab) in Prospective Study for the Treatment of In...

  • May 28, 2022
Alvotech Resolved European Patent Dispute with AbbVie for AVT02 (biosimilar, adalimumab)

Alvotech Resolved European Patent Dispute with AbbVie for AVT02 (biosimilar, adalimumab)

  • April 6, 2022
Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Cancer

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...

  • February 2, 2022
Xbrane Biopharma Seeks to Initiate the Development of Keytruda and Darzalex Biosimilar

Xbrane Biopharma Seeks to Initiate the Development of Keytruda and Darzalex Biosimilar

  • December 13, 2021
Amgen Seeks Interchangeable Status for Its Amjevita (biosimilar, adalimumab)

Amgen Seeks Interchangeable Status for Its Amjevita (biosimilar, adalimumab)

  • November 8, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.